Premium
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue...
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities SIENA, Italy, Dec. 05, 2023...
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors Novel...
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial...
Philogen Announces Clinical Trial Collaboration with MSD The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with...
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand Mumbai...
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich Philogen Publishes New Data on a...
Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology Philogen Announces Publication...
Philogen Provides Corporate Update Philogen Provides Corporate Update Nidlegy™ and Fibromun pivotal clinical trials on track Fibromun shows potent activity in last-line glioblastoma in...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.4 | -2.05128205128 | 19.5 | 19.5 | 18.55 | 4174 | 19.03209536 | DE |
| 4 | -0.1 | -0.520833333333 | 19.2 | 19.75 | 18.05 | 5934 | 18.81863742 | DE |
| 12 | -0.9 | -4.5 | 20 | 21.3 | 18.05 | 4939 | 19.53349459 | DE |
| 26 | -1.2 | -5.91133004926 | 20.3 | 21.9 | 18.05 | 6516 | 20.0781054 | DE |
| 52 | 1 | 5.52486187845 | 18.1 | 21.9 | 16.3 | 8665 | 19.03993516 | DE |
| 156 | 4.64 | 32.0885200553 | 14.46 | 21.9 | 13 | 8792 | 16.798741 | DE |
| 260 | 2.1 | 12.3529411765 | 17 | 21.9 | 12.6 | 12136 | 16.01852449 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
